Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Emma Gardecki
Institutions:
United States Food and Drug Administration,
Center for Devices and Radiological Health,
Harvard University,
Massachusetts General Hospital
Observed institutions:
United States Food and Drug Administration,
Center for Devices and Radiological Health,
Harvard University,
Massachusetts General Hospital
ORCID:
0000-0001-9318-1442
Observed ORCID:
0000-0001-9318-1442
OpenAlex ID:
A5027551279
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma
2024
·
Harshabad Singh
, Kristen E. Lowder
, et al.
·
Nature Communications
·
24
PDF
Reproducible Reporting of the Collection and Evaluation of Annotations for Artificial Intelligence Models
2024
·
Katherine Elfer
, Emma Gardecki
, et al.
·
Modern Pathology
·
17
PDF
Training pathologists to assess stromal tumour‐infiltrating lymphocytes in breast cancer synergises efforts in clinical care and scientific research
2024
·
Amy Ly
, Victor Garcia
, et al.
·
Histopathology
·
14
PDF
Prioritizing cases from a multi-institutional cohort for a dataset of pathologist annotations
2024
·
Victor Garcia
, Emma Gardecki
, et al.
·
Journal of Pathology Informatics
·
1
Abstract CT155: Long term results and ctDNA correlatives for CAPOX BETR: A multi-center phase II trial of capecitabine, oxaliplatin, bevacizumab and trastuzumab for previously untreated HER2 positive metastatic gastroesophageal adenocarcinoma
2023
·
Harshabad Singh
, Kristen E. Lowder
, et al.
·
Cancer Research
Slide-to-Slide Tissue Transfer and Array Assembly From Limited Samples for Comprehensive Molecular Profiling
2023
·
Stephanie E. Weissinger
, N. Zeke Georgantas
, et al.
·
Laboratory Investigation
PDF
Show more works
View as search
Works count:
6
Citation count:
56
H-index:
3
I10-index:
3
Year
Topic
Type